Document is current
Any future updates will be listed below
-
Authors
Spitzl, Daniel
Mergen, Markus https://orcid.org/0009-0007-7753-2784
Endroes, Lukas
Spaeth, Christopher
Trager, Rupert
Braren, Rickmer F.
Eiber, Matthias
Steinhelfer, Lisa
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 10 March 2026
First Online: 21 March 2026
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board of the Technical University of Munich (ethics approval reference number: 87/18S). Due to the retrospective nature of the study, the requirement for written informed consent was waived by the institutional review board.
: Not applicable. No individual patient data or identifiable information are included in this study.
: ME reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. All other authors report no conflict of interest.
